Infectious complications and immunotherapy: old pitfalls and new horizons

Future OncologyVol. 18, No. 22 CommentaryInfectious complications and immunotherapy: old pitfalls and new horizonsAngioletta Lasagna, Irene Cassaniti, Paolo Sacchi, Fausto Baldanti, Raffaele Bruno & Paolo PedrazzoliAngioletta Lasagna *Author for correspondence: Tel.: +39 038 250 2544; E-mail Address: a.lasagna@smatteo.pv.ithttps://orcid.org/0000-0002-9611-1164Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, ItalySearch for more papers by this author, Irene CassanitiMicrobiology & Virology Department, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, ItalySearch for more papers by this author, Paolo SacchiDivision of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, ItalySearch for more papers by this author, Fausto BaldantiMicrobiology & Virology Department, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, ItalyDepartment of Clinical Surgical Diagnostic & Pediatric Sciences, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, ItalySearch for more papers by this author, Raffaele BrunoDivision of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, ItalyDepartment of Clinical Surgical Diagnostic & Pediatric Sciences, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, ItalySearch for more papers by this author & Paolo PedrazzoliMedical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, Pavia, 27100, ItalyDepartment of Internal Medicine & Medical Therapy, University of Pavia, Viale Camillo Golgi 19, Pavia, 27100, ItalySearch for more papers by this authorPublished Online:9 Jun 2022https://doi.org/10.2217/fon-2022-0277AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: immune checkpoint inhibitorsimmune exhaustionimmune reconstitution inflammatory syndromeimmune-related adverse effectsinfectious complicationsIRISviromePapers of special note have been highlighted as: • of interest; •• of considerable interestReferences1. Cai X, Zhan H, Ye Y et al. Current progress and future perspectives of immune checkpoint in cancer and infectious diseases. Front. Genet. 12, 785153 (2021).Crossref, Medline, CAS, Google Scholar2. Morelli T, Fujita K, Redelman-Sidi G, Elkington PT. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax 77(3), 304–311 (2022).Crossref, Medline, Google Scholar3. Martins F, Sofiya L, Sykiotis GP et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16(9), 563–580 (2019). • This paper is a very useful update on the management of the adverse effects of immune checkpoint inhibitors.Crossref, Medline, CAS, Google Scholar4. Xie T, Zhang Z, Qi C et al. The inconsistent and inadequate reporting of immune-related adverse events in PD-1/PD-L1 inhibitors: a systematic review of randomized controlled clinical trials. Oncologist 26(12), e2239–e2246 (2021).Crossref, Medline, CAS, Google Scholar5. Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G. The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin. Infect. Dis. 63(11), 1490–1493 (2016).Crossref, Medline, Google Scholar6. Ross JA, Komoda K, Pal S, Dickter J, Salgia R, Dadwal S. Infectious complications of immune checkpoint inhibitors in solid organ malignancies. Cancer Med. 11(1), 21–27 (2022).Crossref, Medline, CAS, Google Scholar7. Redelman-Sidi G, Michielin O, Cervera C et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin. Microbiol. Infect. 24(Suppl. 2), S95–S107 (2018).Crossref, Medline, Google Scholar8. Liu Z, Liu T, Zhang X et al. Opportunistic infections complicating immunotherapy for non-small cell lung cancer. Thorac. Cancer 11(6), 1689–1694 (2020).Crossref, Medline, Google Scholar9. Abers MS, Lionakis MS, Kontoyiannis DP. Checkpoint inhibition and infectious diseases: a good thing? Trends Mol. Med. 25(12), 1080–1093 (2019).Crossref, Medline, CAS, Google Scholar10. Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J. Dermatol. 45(1), 3–9 (2018). •• This review is a very useful update on the current knowledge of immune reconstitution inflammatory syndrome.Crossref, Medline, Google Scholar11. Fujita K, Terashima T, Mio T. Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis. J. Thorac. Oncol. 11(12), 2238–2240 (2016).Crossref, Medline, Google Scholar12. Tezera LB, Bielecka MK, Ogongo P et al. Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α. eLife 9, e52668 (2020).Crossref, Medline, CAS, Google Scholar13. Lasagna A, Zuccaro V, Sacchi P, Chiellino S, Bruno R, Pedrazzoli P. Risk of reactivation of occult hepatitis B during immunotherapy in cancer treatment: myth, reality or new horizons? Future Oncol. 17(13), 1577–1580 (2021).Link, CAS, Google Scholar14. Knolle PA, Thimme R. Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146, 1193–1207 (2014).Crossref, Medline, CAS, Google Scholar15. Lin X, Lu T, Li S et al. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study. Clin. Transl. Oncol. 23(2), 389–396 (2021).Crossref, Medline, CAS, Google Scholar16. Jing Y, Chen X, Li K et al. Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. J. Immunother. Cancer 10(1), e003779 (2022).Crossref, Medline, Google Scholar17. Hwang JP, Feld JJ, Hammond SP et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J. Clin. Oncol. 38(31), 3698–3715 (2020).Crossref, Medline, CAS, Google Scholar18. Anastasopoulou A, Ziogas DC, Samarkos M, Kirkwood JM, Gogas H. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J. Immunother. Cancer. 7(1), 239 (2019).Crossref, Medline, Google Scholar19. Serra F, Cassaniti I, Lilleri D, Pedrazzoli P, Baldanti F, Lasagna A. Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. Immunotherapy 14(6), 389–393 (2022).Link, CAS, Google Scholar20. Garcia de Moura R, Covre LP, Fantecelle CH et al. PD-1 blockade modulates functional activities of exhausted-like T cell in patients with cutaneous leishmaniasis. Front. Immunol. 12, 632667 (2021).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited ByA case report of pulmonary nocardiosis during pembrolizumab: the emerging challenge of the infections on immunotherapyAngioletta Lasagna, Bryan Arlunno & Ilaria Imarisio24 November 2022 | Immunotherapy, Vol. 14, No. 17 Vol. 18, No. 22 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 56 times History Received 14 March 2022 Accepted 27 May 2022 Published online 9 June 2022 Published in print July 2022 Information© 2022 Future Medicine LtdKeywordsimmune checkpoint inhibitorsimmune exhaustionimmune reconstitution inflammatory syndromeimmune-related adverse effectsinfectious complicationsIRISviromeAuthor contributionsThe authors contributed equally to the present manuscript. All authors approved the submitted version of the manuscript.Financial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending or royalties.No writing assistance was utilized in the production of this manuscript.PDF download